Evidence map›Paper›PMID 41213499›Full record

Trial reportTransplantation and cellular therapy2026

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.

Jason G Dehn, Brent Logan, Stephanie J Lee, Bronwen E Shaw, Steven Devine, Stefan O Ciurea, Mary Horowitz, Naya He, Iskra Pusic, Samer A Srour and 18 more

Abstract readMulticenter StudyClinical Trial
In one paragraph

Trial report in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. New age GVHD prophylaxis regimens: what works for what donor and why.Hematology. American Society of Hematology. Education Program · 2025
    Review
  7. Observational
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Jason G DehnNMDP, Minneapolis, Minnesota. Electronic address: jdehn@nmdp.org.
Brent LoganCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Stephanie J LeeFred Hutchinson Cancer Center, Seattle, Washington.
Bronwen E ShawCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Steven DevineNMDP, Minneapolis, Minnesota; Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, Minnesota.
Stefan O CiureaUniversity of California-Irvine, Irvine, California.
Mary HorowitzCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Naya HeCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Iskra PusicWashington University Barnes Jewish Hospital, St Louis, Washington.
Samer A SrourThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Sally AraiStanford University, Stanford, California.
Mark JuckettUniversity of Minnesota, Minneapolis, Minnesota.
Joseph UbertiKarmanos Cancer Institute Wayne State University, Detroit, Michigan.
LaQuisa HillBaylor College of Medicine, Houston, Texas.
Sumithira VasuThe Ohio State University James Comprehensive Cancer Center, Columbus, Ohio.
William J HoganMayo Clinic, Rochester, Minnesota.
Brandon Hayes-LattinOregon Health Sciences University Knight Cancer Institute, Portland, Oregon.
Peter WesterveltMaineHealth Cancer Care, Scarborough, Maine.
Asad BasheyNorthside Hospital, Atlanta, Georgia.
Nosha FarhadfarUniversity of Florida Shands Healthcare, Gainesville, Florida.
Michael R GrunwaldLevine Cancer Institute Atrium Health, Charlotte, North Carolina.
Eric LeiferNational Heart, Lung and Blood Institute, Bethesda, Maryland.
Heather SymonsJohns Hopkins University, Baltimore, Maryland.
Ayman SaadKing Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Jenny VogelCenter for International Blood and Marrow Transplant Research, NMDP, Minneapolis, Minnesota.
Connor EricksonCenter for International Blood and Marrow Transplant Research, NMDP, Minneapolis, Minnesota.
Kelly BuckNMDP, Minneapolis, Minnesota.
Joseph PidalaH. Lee Moffitt Cancer Center, Tampa, Florida.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
BMT CTN Core - Fred Hutchinson Cancer CenterUG1HL069246 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 2017 to 2026
$2.2M
Targeting HIV and EBV Antigens in Patients with HIV LymphomaUG1HL108945 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Catherine M. Bollard, HELEN E HESLOP · 2017 to 2026
$2.1M
Core Clinical Centers for the Blood and Marrow Transplant Clinical Trials Network (UG1)UG1HL108987 · NHLBI · H. LEE MOFFITT CANCER CTR & RES INST · PI Joseph A Pidala · 2017 to 2026
$2.1M
BMT CTN Core - University of MinnesotaUG1HL069290 · NHLBI · UNIVERSITY OF MINNESOTA · PI Mark Juckett, Margaret L MacMillan · 2017 to 2026
$1.9M
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials NetworkUG1HL138645 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JOHN LEVINE · 2017 to 2026
$1.9M
Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell TherapiesUG1HL109137 · NHLBI · WASHINGTON UNIVERSITY · PI Iskra Pusic · 2017 to 2026
$1.9M
Translational Research in Blood and Marrow TransplantationUG1HL069310 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI RICHARD J JONES · 2017 to 2026
$1.6M
NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069246NHLBI NIH HHS UG1 HL069290NHLBI NIH HHS UG1 HL069310NHLBI NIH HHS UG1 HL108945NHLBI NIH HHS UG1 HL108987NHLBI NIH HHS UG1 HL109137NHLBI NIH HHS UG1 HL138645
6 · The paper itself

Abstract

Patients requiring allogeneic hematopoietic cell transplantation (HCT) have variable likelihoods of identifying an 8/8 HLA-matched unrelated donor (MUD). A Search Prognosis calculator can estimate the likelihood. This study (NCT#03904134; https://clinicaltrials.gov/study) evaluates if using a Search Prognosis algorithm results in similar incidence of transplant between patients Very Likely (>90%) versus Very Unlikely (<10%) to have a MUD. An additional objective included understanding barriers resulting in a delay or cancellation of a patient transplant. The national multicenter Blood and Marrow Transplant Clinical Trial Network (BMT CTN) 1702 interventional trial utilized Search Prognosis-based biologic assignment to guide donor selection. HCT eligible patients at participating transplant centers were invited to enroll. Patients assigned to the Very Likely arm were to proceed with MUD, while Very Unlikely were to utilize alternative donors. A third stratum, Less Likely (∼25%), were observed under standard center practices, but were not part of the primary objective. We report here the cumulative incidence of HCT by Search Prognosis group and barriers to HCT. Evaluable patients included 1751 of which 413 (24%) were from racial/ethnic minorities. Seach Prognosis was 958 (55%) Very Likely, 517 (30%) Less Likely, and 276 (16%) Very Unlikely. About 1171 (67%) received HCT, 384 (22%) died without HCT, and 196 (11%) remained alive without HCT. Among the 1234 patients (Very Likely versus Very Unlikely), the adjusted cumulative incidence (95% CI) of HCT at 6 months was 59.8% (56.7 to 62.8) in Very Likely versus 52.3% (46.1 to 58.5) in Very Unlikely (P = .113). Median time to HCT were similar in all Seach Prognosis groups. The predominant barriers resulting in a delay or cancellation of transplant were due to poor patient health (59%). Around 9% of delays and cancellations were attributed to excellent patient disease response, with only 14% of delays and 2% of cancellations due to donor reasons. A prospective Search Prognosis-based algorithm can be effectively implemented in a national multicenter clinical trial, with donor related barriers to transplant representing a small proportion of cases. This approach resulted in rapid alternative donor identification and no statistical difference in rates of HCT in patients Very Likely and Very Unlikely to find a MUD.

Indexed as

Donor SelectionHematopoietic Stem Cell TransplantationTissue DonorsUnrelated DonorsAdolescentAdultAgedFemaleHumansMaleMiddle AgedPrognosisTransplantation, HomologousYoung AdultDonor search prognosisDonor selectionTransplantation

Identifiers

PMID41213499
PMCPMC12779121

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.